Date: 20-Nov-2019

Novartis eyes $1B sales with FDA nod for targeted sickle cell disease drug Adakveo

Another candidate for Novartis' future blockbuster club is here. Friday, the Swiss drugmaker won FDA approval for Adakveo, the first targeted therapy to prevent the painful vaso-occlusive crises (VOCs) that come along with sickle cell disease. The nod came weeks ahead of schedule, even on top of a priority review doled out in July. Novartis has priced the new drug, meant for patients 16 and older, at a wholesale acquisition cost (WAC) of $2,357 per vial. As it’s prescribed based on weight, most patients would take three or four vials a month. That would translate into WACs of $7,071, or $9,428, per month.